Mirae Asset Global Investments Reduces Bristol Myers Squibb Stake

The investment firm sold nearly 100,000 shares of the pharmaceutical company in Q4 2025.

Apr. 17, 2026 at 11:05am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white macro photograph of the inner workings of a large banking machine, capturing the industrial strength and technical precision of financial institutions.An extreme close-up of the intricate gears and mechanisms that power the global financial system, hinting at the complex infrastructure underlying major investment decisions.Princeton Today

Mirae Asset Global Investments Co. Ltd. reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.4% during the fourth quarter of 2025, according to a recent SEC filing. The firm sold 96,485 shares, leaving it with 2,115,360 shares worth approximately $114.1 million as of the end of the quarter.

Why it matters

This transaction provides insight into the investment strategy of Mirae Asset Global Investments, one of the largest asset management firms in Asia. The reduced stake in Bristol Myers Squibb, a major pharmaceutical company, could signal a shift in the firm's portfolio allocation or a reassessment of the stock's prospects.

The details

Mirae Asset Global Investments Co. Ltd. is an investment management firm based in South Korea with over $600 billion in assets under management globally. The firm's reduced position in Bristol Myers Squibb was part of broader changes to its U.S. equity holdings during the fourth quarter.

  • Mirae Asset Global Investments filed the Q4 2025 disclosure with the SEC on April 17, 2026.
  • The firm sold 96,485 shares of Bristol Myers Squibb during the fourth quarter of 2025.

The players

Mirae Asset Global Investments Co. Ltd.

A South Korean investment management firm with over $600 billion in assets under management globally.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the shifting investment landscape as major firms reevaluate their positions in pharmaceutical companies like Bristol Myers Squibb. The reduced stake could signal broader market trends or specific concerns about the company's outlook.